MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1371/journal.pone.0304918

Медицинская библиотека · PloS one · 2025

Prospective follow-up of New York City residents with e-cigarette, or vaping product use-associated lung injury-2020-2021.

Tannert Niang Kathryn M, Grasso Aviva B, Debchoudhury Indira, Bushman Dena, Jasek John P, Fairclough Monique A, Van Oss Katherine R, Chamany Shadi, LaSane Kendall D, Franklin Sharraine M, Talati Achala K

СтатьяПеревод в очереди

Аннотация

BACKGROUND

A multistate outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) occurred in 2019. Because of EVALI's novelty and severity, the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) prospectively assessed sequelae among NYC residents who received an EVALI diagnosis in 2019.

METHODS

Using existing NYC EVALI surveillance data, DOHMH attempted contact with all living residents who received an EVALI diagnosis in 2019 and conducted 3 waves of telephone interviews during April 2020-March 2021. Interview questions were adapted from the Centers for Disease Control and Prevention's EVALI case report form and validated surveys. Baseline differences between respondents and nonrespondents were assessed with Chi-square and Fisher's exact tests; clinical and behavioral characteristics and open-ended responses were summarized.

RESULTS

In 2019, 53 NYC residents received an EVALI diagnosis; 33 (67%), 14 (29%), and 18 (37%) of 49 living residents participated in the first, second, and third interviews, respectively. Interviews occurred after outpatient diagnosis (6%) or hospital discharge (94%), at a median of 8, 11, and 17 months for each wave. Respondents (N = 33) and nonrespondents (N = 16) did not differ by sex, age, hospitalization status or length. Respondents were mostly male (70%), had a median age of 23 years (range: 16-63 years), and all reported using vaping or e-cigarette products (vaping) with tetrahydrocannabinol (88%), nicotine (49%), or cannabidiol (9%) before diagnosis. Respiratory (first and second interviews) and gastrointestinal (third interviews) symptoms were most commonly reported. Sixteen respondents (49%) reported any new diagnosis during follow-up. Fifteen to 29% of respondents reported vaping at each interview; 58%-93% reported recent non-vaped cannabinoid use.

CONCLUSION

NYC residents with EVALI reported symptoms throughout the follow-up period, and approximately half reported newly diagnosed health conditions. Further studies are needed to understand EVALI's relationship with symptoms and health conditions.

Для цитирования: Tannert Niang Kathryn M, Grasso Aviva B, Debchoudhury Indira, Bushman Dena, Jasek John P, Fairclough Monique A, Van Oss Katherine R, Chamany Shadi, LaSane Kendall D, Franklin Sharraine M, Talati Achala K. Prospective follow-up of New York City residents with e-cigarette, or vaping product use-associated lung injury-2020-2021.. PloS one. 2025. DOI: 10.1371/journal.pone.0304918.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.